News
-
22.12.2020Captor Therapeutics and Sosei Heptares Enter Strategic Collaboration
Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
-
22.10.2020Captor Therapeutics as one of the „Scrip’s 10 To Watch”
We have been selected as one of the „Scrip’s 10 To Watch” companies at #BIOEurope Digital 2020!
-
24.04.2020A new project in the area of autoimmune diseases
We have received over 27 M PLN grant for a new project!
-
05.03.2020Advancing the technological platform
A new grant will support...
-
21.02.2020Captor's review article
Our review on protein degradation technology has been published in "Technology Transfer and Entrepreneurship"...
-
30.01.2020Captor's oncological program received funding
Discovery and development of a new clinical drug candidate in the treatment of hepatocellular carcinoma...
-
19.12.2019Our new chemistry lab
We are happy to announce that our brand new chemistry lab is ready!
-
02.12.2019Dr Tom Shepherd joins our team
Tom Shepherd, Ph.D. as Captor Therapeutics' Chief Business Officer (CBO)...
-
30.07.2019Biotech of the Week in Labiotech
Labiotech about Captor Therapeutics...
-
17.05.2019CEBioForum Award 2019
We received the CEBioForum Award (Individual Prize)...